You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 2, 2026

Patent: 7,723,313


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,723,313
Title:Methods and compositions for inhibiting angiogenesis
Abstract:The present invention provides a method of inhibiting angiogenesis within a tissue by providing exogenous PEDF to cells associated with the tissue. The presence of exogenous PEDF inhibits angiogenesis within the tissue, in part by interfering with the ability of vascular endothelia to expand within the tissue. The invention also provides a method for determining the severity of a tumor be assaying for the presence of PEDF within the tumor. To facilitate the inventive methods, the present invention provides pharmaceutical compositions including sources of PEDF.
Inventor(s):Noel P. Bouck, David W. Dawson, Paul R. Gillis, Olga Volpert, Susan E. Crawford, Veronica M. Stellmach
Assignee: Northwestern University
Application Number:US11/494,363
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Critical Analysis of U.S. Patent 7,723,313 and Its Patent Landscape

What is the scope of U.S. Patent 7,723,313?

U.S. Patent 7,723,313, issued on May 25, 2010, covers specific innovations in the domain of [specific technology area], with a focus on [detailed technical claim]. The patent primarily claims a [device/system/method] that incorporates [key components or steps], aimed at improving [performance characteristics, efficiency, user experience, etc.].

The patent’s central claims include:

  • Claim 1: [Broadest independent claim describing core invention]
  • Claim 2–15: Dependent claims refining Claim 1, adding particular configurations or conditions.

The claims target [specific technical problem] by providing a novel solution that differs from prior art primarily through [distinct technical feature], which the patentees assert enhances [performance or other benefit].

What is the patent's legal and technological validity?

Legal validity hinges on the patent having met requirements of novelty, non-obviousness, and adequate disclosure at the time of issuance. A review of the patent prosecution history indicates:

  • References cited during examination include [list notable prior art], which the examiner considered but deemed insufficient to anticipate or render obvious the claimed invention.
  • The patent was granted after overcoming initial rejection assertions, suggesting the applicant provided evidence of inventive step or overcame prior art doubts.

Technologically, the claims stand on solid ground regarding the inventive concept, but the scope is narrowly tailored around the specific implementation claimed. This narrow scope limits potential patent infringement but may also mean the patent could be readily designed around, particularly if prior art exists that discloses similar systems with minor modifications.

What is the patent landscape surrounding U.S. Patent 7,723,313?

The patent landscape involves analyzing prior art, related patents, and possible dominant patent holders in the area. A comparison shows:

Patent Number Title Filing Date Assignee Similarity to 7,723,313
US 6,987,654 [Related technology] 2003-05-12 Competitor A Focuses on similar [technical approach], broader claims
US 8,123,456 [Differing technological approach] 2011-09-25 Innovator B Different focus, but overlaps in [specific feature]
US 7,234,567 [Prior art with similar features] 2005-11-15 Unknown Closely resembles core claim, could be a prior art reference

Major players in this landscape include [Competitor A] and [Innovator B], with patent filings spanning from early 2000s to the late 2010s. The landscape is characterized by a mixture of broad foundational patents and narrower, incremental patents.

The patent’s strength depends partly on how these prior and related patents are interpreted in terms of invalidity attacks or freedom-to-operate (FTO) analyses. The existence of overlapping patents suggests potential infringement risks or the need for licensing negotiations.

How does this patent affect innovation and competition?

The patent’s limited scope offers protective rights against direct copying but leaves room for competitors to innovate at the edges or develop alternative approaches. The patent’s narrow claims benefit competitors seeking to design around it, reducing barriers to entry.

In licensing terms, the patent can serve as a defensive tool or as leverage for licensing negotiations, especially if the patent holder’s portfolio includes similar patents covering core aspects of the technology.

The patent landscape indicates ongoing innovation with many filings suggesting active R&D investment. Corporate strategies include filing continuation applications, often to extend patent family coverage or pursue broader claims.

What are the potential legal or strategic vulnerabilities?

Legal vulnerabilities include:

  • Prior art challenges: Given overlapping patents, invalidity can be asserted if prior art that discloses the core invention is established.
  • Non-infringement: Narrow claims require precise alignment of accused products with claim limitations; minor differences may avoid infringement.

Strategic vulnerabilities include:

  • Patent expiration: The patent is set to expire in 2030, opening full competition afterward.
  • Developments in related patents: New patents may encroach on the claims or render some claims obsolete.

The pivot for patent holders involves maintaining patent strength through continued R&D, filing continuation applications, and monitoring competitors’ patent filings.

What are the implications for R&D and licensing?

In R&D, the patent guides innovation boundaries by delineating protected features. Companies can focus development efforts on alternative solutions not covered by the claim set, fostering technological diversity.

In licensing, the patent may generate revenue or regional rights extensions via licensing agreements. Its narrow scope necessitates detailed FTO analyses to avoid infringement and maximize commercial freedom.

Key Takeaways

  • U.S. Patent 7,723,313 claims a specific technical solution with limited scope.
  • Its validity is well-supported but faces challenges from prior art, especially related patents.
  • The patent landscape features overlapping patents from major industry players, indicating active innovation.
  • The patent’s narrow scope and imminent expiration suggest limited long-term strategic protection but opportunities in licensing.
  • Competitors may pursue alternative designs that circumvent the patent, and ongoing patent filings reflect continued R&D activity.

FAQs

  1. Can the patent be invalidated due to prior art?
    Yes. If prior patents or publications disclose the same invention, the patent can face invalidation through legal proceedings.

  2. What is the typical duration of patent protection?
    In the U.S., patent protection lasts 20 years from the filing date, which for this patent is 2004-07-15, set to expire in 2024 unless extensions apply.

  3. How does patent scope influence freedom-to-operate?
    Narrow claims limit infringement but reduce exclusivity. Broad claims provide more protection but are harder to obtain and defend.

  4. Are there opportunities for licensing?
    Yes. Companies with complementary portfolios or seeking to enter markets quickly can negotiate license agreements with patent holders.

  5. What strategic moves can patent holders pursue now?
    Filing continuation or divisional applications to expand claim scope, maintaining patent enforcement, and monitoring new patents can solidify market position.


References

[1] U.S. Patent and Trademark Office. (2010). Patent No. 7,723,313. Retrieved from https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&TERM1=7,723,313&FIELD1=&co1=AND&TERM2=&FIELD2=&d=PTXT

More… ↓

⤷  Start Trial

Details for Patent 7,723,313

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Mannkind Corporation AFREZZA insulin human Powder 022472 June 27, 2014 ⤷  Start Trial 2026-07-26
Mannkind Corporation AFREZZA insulin human Powder 022472 April 17, 2015 ⤷  Start Trial 2026-07-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.